Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telix Pharmaceuticals ( (AU:TLX) ) has shared an update.
Telix Pharmaceuticals has notified the market of the cessation of certain equity incentive instruments, specifically 173,861 share appreciation rights (code TLXAO) and 43,428 performance share appreciation rights (code TLXAW). These instruments lapsed on 30 March 2026 because the performance or vesting conditions attached to them were not met or became incapable of being satisfied.
The lapse of these conditional rights results in a reduction of potential future dilution from the company’s share-based remuneration programs. This development may slightly alter the structure of Telix’s long-term incentive pool and could indicate that specific performance or operational targets tied to these awards were not achieved within the relevant period.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$27.40 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is a biopharmaceutical company listed on the ASX under the ticker TLX. The company operates in the pharmaceutical and life sciences sector, focusing on the development and commercialisation of medical technologies and therapies, as implied by its use of share-based incentive rights for employees and executives.
Average Trading Volume: 3,408,551
Technical Sentiment Signal: Buy
Current Market Cap: A$5.02B
For an in-depth examination of TLX stock, go to TipRanks’ Overview page.